Phentermine has been prescribed for weight loss since 1959. GLP-1 medications have reshaped weight management since 2021. They're both appetite-suppressing medications, but the comparison between them is not a close one on efficacy — and the gap is wider than many patients realize.
At the same time, phentermine costs $30–60/month as a generic. Brand-name Wegovy costs $1,300–$1,500/month. The economics matter.
This guide compares GLP-1 medications and phentermine across the dimensions that matter for patients making a practical decision: how they work, how much weight they produce, side effects, cost, duration of use, and who each option is actually right for in 2026.
The Quick Comparison
| GLP-1 Medications | Phentermine | |
|---|---|---|
| Examples | Ozempic, Wegovy, Mounjaro, Zepbound | Adipex-P, Lomaira (generics available) |
| Drug class | GLP-1 receptor agonist | Sympathomimetic amine (stimulant) |
| Mechanism | Mimics GLP-1 hormone; reduces hunger, slows gastric emptying, acts on reward circuits | Releases norepinephrine in hypothalamus; suppresses appetite via stimulant effect |
| Administration | Weekly injection (most formulations) | Daily oral pill |
| Average weight loss | 15–22% body weight (semaglutide/tirzepatide) | 5–7% body weight (12-week trials) |
| Approved duration | Long-term/chronic weight management | Short-term (typically 12 weeks) |
| Cardiovascular effect | Heart rate may increase moderately; neutral or beneficial cardiac outcomes in T2D trials | Increases heart rate and blood pressure |
| Controlled substance | No | Yes — Schedule IV |
| Brand-name cost/month | $1,300–$1,500 (Wegovy) | ~$150–$250 |
| Generic/compounded cost/month | $100–$450 (compounded semaglutide) | ~$30–$60 |
| Insurance coverage | Variable; often limited for weight management | Often covered as a generic |
How They Work: Different Mechanisms
GLP-1 Medications
GLP-1 receptor agonists mimic glucagon-like peptide-1, a hormone produced naturally by the intestines after eating. When GLP-1 receptors are activated:
- Insulin secretion is stimulated in response to blood glucose (glucose-dependent; this is why hypoglycemia risk is low without other diabetes medications)
- Glucagon is suppressed, reducing glucose output from the liver
- Gastric emptying slows — food stays in the stomach longer, extending satiety
- Hypothalamic hunger signals are reduced — the brain receives signals to eat less
- Reward circuits are modulated — GLP-1 receptors in the nucleus accumbens and VTA appear to reduce hedonic eating drive
This combination of gut, pancreatic, and brain effects explains why GLP-1 medications produce substantially more weight loss than earlier appetite suppressants.
Phentermine
Phentermine is a sympathomimetic amine — structurally related to amphetamine — that works primarily by stimulating the release of norepinephrine in the hypothalamus, triggering the "fight-or-flight" response that suppresses appetite as a side effect.
The mechanism is older and less targeted:
- Norepinephrine release reduces appetite via the hypothalamus
- Heart rate and blood pressure typically increase (stimulant effect)
- Dopamine and serotonin may also be partially affected
Phentermine was approved by the FDA in 1959 — before the modern framework for obesity pharmacotherapy existed. It remains available because it does work in the short term, the generic is widely accessible and cheap, and there is a large established prescribing history.
Efficacy: The Weight Loss Difference
The clinical evidence is unambiguous: GLP-1 medications produce far more weight loss.
Phentermine Outcomes
Most phentermine trials are short-duration (12 weeks, matching the approved use window) and were conducted decades ago, limiting the quality of evidence by modern standards. The consistent finding:
- Average weight loss: 5–7% of body weight over 12 weeks
- At 12 weeks, most patients regain weight when phentermine is discontinued
- No long-term weight maintenance trial data comparable to GLP-1 trials
For a 250-pound patient: average phentermine weight loss = 12–17 lbs over 12 weeks.
GLP-1 Medication Outcomes
| Trial | Drug | Duration | Average Weight Loss |
|---|---|---|---|
| STEP 1 | Semaglutide 2.4mg (Wegovy) | 68 weeks | −14.9% body weight |
| STEP 4 | Semaglutide 2.4mg | 68 weeks (continuation) | Maintained/continued loss |
| SURMOUNT-1 | Tirzepatide 15mg (Zepbound) | 72 weeks | −22.5% body weight |
For a 250-pound patient:
- Semaglutide (Wegovy): average loss = ~37–40 lbs over 68 weeks
- Tirzepatide (Zepbound): average loss = ~55–60 lbs over 72 weeks
- Phentermine: average loss = ~12–17 lbs over 12 weeks (short-term only)
The caveat: averages mask individual variation. Some patients respond exceptionally well to phentermine; some respond modestly to GLP-1 therapy. But across populations, the GLP-1 advantage is consistent and substantial.
Phentermine + Topiramate (Qsymia): A Middle Ground
Qsymia is an FDA-approved combination of phentermine and the anticonvulsant topiramate, approved for chronic weight management in 2012. Clinical trial data:
- Average weight loss: ~10–11% body weight at higher doses over 1 year
- Significantly better outcomes than phentermine alone
- Still well below semaglutide or tirzepatide outcomes
Qsymia is worth knowing about as an option that exceeds phentermine-alone results at lower cost than GLP-1 medications. Generic Qsymia is available for approximately $150–$200/month, though brand pricing is higher.
Side Effects: A Different Profile
The side effect profiles differ significantly — not necessarily in severity, but in type.
GLP-1 Medications
- GI effects (most common): nausea, vomiting, diarrhea, constipation — particularly during dose escalation
- Reduced appetite (intended)
- Moderate heart rate increase (~1–4 bpm) — generally clinically insignificant
- Serious but rare: pancreatitis, gallbladder disease
- Boxed warning: thyroid C-cell tumor risk (based on rodent studies; not established in humans)
- No addiction potential: not a controlled substance
Phentermine
- Cardiovascular effects (significant): elevated heart rate, elevated blood pressure — this is a stimulant
- CNS/stimulant effects: insomnia, nervousness, restlessness, anxiety, irritability
- Dry mouth
- Physical dependence potential: Schedule IV controlled substance; tolerance develops
- Contraindicated in: cardiovascular disease, hypertension, hyperthyroidism, glaucoma, history of substance use disorder, MAO inhibitor use
- Not for long-term use: the cardiovascular profile and dependence potential limit it to short-term prescribing
For patients with anxiety disorders, insomnia, elevated blood pressure, or cardiovascular risk, phentermine's stimulant profile is a meaningful clinical concern. GLP-1 medications have a more GI-focused side effect profile with fewer cardiovascular and CNS concerns.
Who Should Still Consider Phentermine
Given the efficacy gap, there are scenarios where phentermine remains a reasonable clinical choice in 2026:
Cost barriers: At $30–60/month as a generic, phentermine is accessible to patients without insurance coverage who cannot afford compounded semaglutide ($100–$450/month). For a patient with no access to GLP-1 therapy at any price point, phentermine offers meaningful short-term benefit.
Short-term goal with specific timeline: If a patient needs to lose 10–15 lbs for a defined reason (surgery preparation, a specific event) in 12 weeks and doesn't intend to pursue long-term pharmacotherapy, phentermine's short-term efficacy is appropriate to the goal.
Bridge during GLP-1 titration: Some clinicians use phentermine as a short-term bridge while a patient titrates up on a GLP-1 medication — getting early appetite suppression while the GLP-1 reaches therapeutic effect. This is off-label, requires careful clinical management, and is not standard practice.
Cardiovascular clearance and specific preference: Some patients tolerate and prefer the stimulant-based appetite suppression profile. This is a valid individual preference where the clinical picture supports it.
Who Should Not Use Phentermine
The cardiovascular profile of phentermine makes it contraindicated or high-risk for patients with:
- Known heart disease, coronary artery disease, or arrhythmias
- Uncontrolled hypertension
- Hyperthyroidism
- Glaucoma
- History of stimulant use disorder or substance use disorder
- Current or recent MAO inhibitor use
- Pregnancy
For this population, GLP-1 medications — which are cardiac-neutral or beneficial in cardiovascular outcome trials — are the safer pharmacological choice if weight loss pharmacotherapy is appropriate.
Cost and Access
| Option | Monthly Cost | Notes |
|---|---|---|
| Phentermine (generic) | ~$30–$60 | Widely available at pharmacies; often covered by insurance |
| Qsymia (phentermine + topiramate) | $150–$200 (generic); higher for brand | More effective than phentermine alone |
| Compounded semaglutide (telehealth) | ~$100–$450 | Requires telehealth prescription; quality varies by provider |
| Wegovy (brand semaglutide 2.4mg) | ~$1,300–$1,500 | With insurance benefit, copay may be manageable |
| Zepbound (brand tirzepatide) | ~$1,060–$1,400 | Novo Nordisk and Eli Lilly savings programs available |
For patients paying fully out of pocket, the cost hierarchy is clear. The question is whether the additional ~$70–$400/month of compounded semaglutide over phentermine is justified by the substantially better weight loss outcomes and chronic vs short-term use approval. For most patients pursuing meaningful long-term weight management, the answer is yes — but affordability is a real constraint.
The Bottom Line
Phentermine remains a legitimate, widely-prescribed medication for short-term weight loss. It's cheap, accessible, and works for its intended purpose.
GLP-1 medications produce roughly 2–4x more weight loss, are approved for long-term use, have a better cardiovascular safety profile, and — through compounded telehealth options — are now accessible at $100–$450/month. For patients who can access GLP-1 therapy, the long-term outcomes are substantially better.
Phentermine's primary advantages in 2026 are cost and accessibility: it remains a meaningful option for patients for whom GLP-1 therapy is financially out of reach. For everyone else, the evidence favors GLP-1 medications for durable weight management.
Frequently Asked Questions
Is phentermine or a GLP-1 medication better for weight loss?
GLP-1 medications produce significantly more weight loss. Semaglutide produces an average of 15% body weight loss; tirzepatide averages 20-22%. Phentermine produces approximately 5-7% over its approved 12-week window. GLP-1 medications are also approved for long-term use, unlike phentermine. Phentermine's advantage is cost: the generic runs $30-60/month versus $100-450/month for compounded GLP-1 options.
Can I take phentermine and a GLP-1 medication together?
This is not a standard FDA-approved protocol and is not generally recommended without explicit clinical supervision. Phentermine combined with topiramate (Qsymia) is a proven FDA-approved combination. If you're interested in combination approaches, discuss with a prescriber who can evaluate your cardiovascular history and the specific combination being considered.
How long can you take phentermine?
Phentermine is FDA-approved for short-term use — typically up to 12 weeks. It is a Schedule IV controlled substance. This is a fundamental difference from GLP-1 medications, which are approved for chronic, long-term weight management.
Is phentermine still prescribed in 2026?
Yes. Phentermine remains widely prescribed for obesity, primarily because it is dramatically cheaper than GLP-1 medications and available as a low-cost generic. For patients who cannot access or afford compounded semaglutide or tirzepatide, phentermine remains a legitimate pharmacological option despite its more modest efficacy.
Compare GLP-1 telehealth platforms offering semaglutide and tirzepatide at transparent pricing on our provider comparison page. Filter by cost, state availability, and medication type.